drugset / Trial / NCT01175616

Creatine Augmentation in Veterans With SSRI-Resistant Major Depression

NCT01175616

Phase 4 Withdrawn University of Utah
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether creatine will be helpful as an adjunctive treatment for treatment-resistant major depressive disorder (MDD) in female and male Veterans. We hypothesize that Veterans receiving creatine will show decreased depressive symptoms as measured by the Montgomery-Asberg Depression Rating Scale (MADRS). We will also use 31-Phosphorus Magnetic Resonance Spectroscopy (31-P MRS) brain scans to compare levels of neurochemicals related to energy metabolism in the brain, before-and-after treatment with creatine, and between healthy controls and MDD participants.

Timeline

Start
2012-09
Primary completion
2014-04
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Creatine Other / unclassified 5 g Oral